Tranexamic Acid

CHICAGO — Tranexamic acid in total ankle arthroplasty and hindfoot fusion may reduce the number of superficial infections, provide shorter time to union and decrease rates of delayed wound healing, according to results presented here.

WASHINGTON — Tranexamic acid administered intravenously before and after noncardiac surgery lowered the risk for life-threatening, major and critical organ bleeding compared with placebo, according to results of the POISE-3 trial.

Tranexamic acid decreases postoperative pain, swelling, drainage output, joint aspirations and hemarthrosis in patients undergoing arthroscopic surgery, with no increase in complications or operative time, results showed.

Prophylactic tranexamic acid administration — on top of routine uterotonics — is effective in lowering postpartum blood loss and limiting hemoglobin drop in women undergoing cesarean delivery, according to a meta-analysis.

According to published results, tranexamic acid administration reduced intraoperative blood loss and decreased the risk of 90-day complications for patients with preoperative coagulopathy who underwent total hip or knee arthroplasty.

According to published results, tranexamic acid use in high-risk patients during total hip and total knee arthroplasties was associated with decreased odds of blood transfusion with no increased risk for complications.

Treatment with tranexamic acid significantly reduced the incidence of calculated estimated postpartum blood loss of more than 1000 mL or red‐cell transfusions within 2 days of cesarean delivery, according to a randomized controlled trial.

For patients with a history of coronary artery disease or coronary stents who undergo total joint arthroplasty, use of topical and intravenous tranexamic acid is safe, according to published results.

Tranexamic acid was associated with reduced perioperative bleeding in all types of shoulder surgeries and may reduce postoperative pain and operation time, according to published results.

The addition of tranexamic acid prophylaxis to platelet transfusion did not reduce bleeding among patients with blood cancers and severe thrombocytopenia, according to study results presented at the virtual ASH Annual Meeting and Exposition.